Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.46 |
| ▸ | BCR | P11274 | 7/20 | 0.46 |
| ▸ | PRKCA | P17252 | 4/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | CAMK2D | Q13557 | 4/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.42 |
| ▸ | SRC | P12931 | 4/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | PRKACG | P22612 | 1/20 | 0.41 |
| ▸ | PRKACB | P22694 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17152799 | 0.86 | ABL1 (0.55) | ABL1BCRPRKCAPRKCDEGFR | |
| SCHEMBL17153250 | 0.81 | ABL1 (0.48) | ABL1BCRPRKCAPRKCDEGFR | |
| SCHEMBL17152800 | 0.80 | PIK3CG (0.48) | ABL1BCRPRKCAPRKCDCAMK2D | |
| SCHEMBL17153042 | 0.79 | ABL1 (0.60) | ABL1BCRPRKCAPRKCDEGFR | |
| SCHEMBL17153234 | 0.77 | CDC7 (0.40) | ABL1BCRPRKCAPRKCDEGFR | |
| SCHEMBL12921620 | 0.75 | PIK3CA (0.51) | ABL1BCRPRKCAPRKCDEGFR | |
| SCHEMBL3510842 | 0.75 | ABL1 (0.75) | ABL1BCRPRKCAPRKCDEGFR | |
| SCHEMBL17152811 | 0.74 | CCNT1 (0.49) | ABL1BCRPRKCAPRKCDEGFR | |
| SCHEMBL6955263 | 0.73 | PIK3CG (0.59) | PRKCAPRKCDEGFRPIK3CAPIK3CB | |
| SCHEMBL17153131 | 0.72 | ABL1 (0.47) | ABL1BCRPRKCAPRKCDEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017509-B2 | Macrocylic pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-10 | — | — | US | disclosed |
| EP-3126364-B1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-07 | — | — | EP | disclosed |
| WO-2015150555-A1 | MACROCYLIC PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017509-B2 | Macrocylic pyrimidine derivatives | EEF2K, VPS26B, VPS28 | ABL1 3037/4885BCR 4756/4885PRKCA 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.